Amundi
ACAD icon

Amundi’s Acadia Pharmaceuticals ACAD Stock Holding History

Amundi’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$596K Buy
26,753
+8,508
+47% +$203K ﹤0.01% 1480
2025
Q4 		$487K Sell
18,245
-4,210
-19% -$101K ﹤0.01% 1482
2025
Q3 		$485K Buy
22,455
+2,054
+10% +$48.6K ﹤0.01% 1339
2025
Q2 		$433K Buy
+20,401
New +$379K ﹤0.01% 1413

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Amundi's ACAD Position: Q1 2026 in Review

Amundi increased its Acadia Pharmaceuticals (ACAD) stake by 47% in Q1 2026, buying an estimated $203K and bringing the position to 26,753 shares worth $596K. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

Amundi first reported a position in ACAD in Q2 2025 and has held it in 4 quarters since. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Amundi held 26,753 shares of Acadia Pharmaceuticals worth $596K as of Q1 2026.
  • Amundi bought 8,508 Acadia Pharmaceuticals shares in Q1 2026, an estimated $203K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1480 holding.
  • Amundi first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.